Intech Investment Management LLC Sells 24,385 Shares of Cencora, Inc. (NYSE:COR)

Intech Investment Management LLC trimmed its position in shares of Cencora, Inc. (NYSE:COR - Free Report) by 33.4% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 48,627 shares of the company's stock after selling 24,385 shares during the period. Intech Investment Management LLC's holdings in Cencora were worth $10,926,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. JFS Wealth Advisors LLC boosted its stake in Cencora by 63.0% during the 4th quarter. JFS Wealth Advisors LLC now owns 119 shares of the company's stock valued at $27,000 after purchasing an additional 46 shares during the period. SBI Securities Co. Ltd. acquired a new position in Cencora during the 4th quarter valued at about $30,000. Kentucky Trust Co acquired a new position in Cencora during the 4th quarter valued at about $33,000. Householder Group Estate & Retirement Specialist LLC boosted its stake in Cencora by 85.2% during the 4th quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company's stock valued at $33,000 after purchasing an additional 69 shares during the period. Finally, WASHINGTON TRUST Co boosted its stake in Cencora by 37.7% during the 4th quarter. WASHINGTON TRUST Co now owns 168 shares of the company's stock valued at $38,000 after purchasing an additional 46 shares during the period. 97.52% of the stock is owned by institutional investors and hedge funds.

Cencora Trading Down 0.3 %

Shares of COR stock traded down $0.93 during trading hours on Friday, reaching $266.91. 6,526,576 shares of the stock traded hands, compared to its average volume of 1,376,560. Cencora, Inc. has a 1-year low of $214.77 and a 1-year high of $271.08. The business has a fifty day moving average price of $250.62 and a 200 day moving average price of $240.06. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40. The firm has a market capitalization of $51.76 billion, a PE ratio of 37.97, a PEG ratio of 1.31 and a beta of 0.51.

Remove Ads

Cencora (NYSE:COR - Get Free Report) last released its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. On average, equities research analysts forecast that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, March 3rd. Investors of record on Friday, February 14th were given a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a yield of 0.82%. The ex-dividend date was Friday, February 14th. Cencora's payout ratio is presently 31.29%.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on COR shares. Mizuho assumed coverage on shares of Cencora in a research note on Wednesday, December 4th. They set an "outperform" rating and a $280.00 target price for the company. Evercore ISI boosted their price target on shares of Cencora from $270.00 to $280.00 and gave the stock an "outperform" rating in a research report on Thursday, February 6th. StockNews.com upgraded shares of Cencora from a "hold" rating to a "buy" rating in a research report on Wednesday, March 12th. Wells Fargo & Company boosted their price target on shares of Cencora from $251.00 to $274.00 and gave the stock an "equal weight" rating in a research report on Friday, March 14th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Cencora from $289.00 to $301.00 and gave the stock an "overweight" rating in a research report on Friday, January 24th. Two investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Cencora currently has a consensus rating of "Moderate Buy" and a consensus target price of $280.20.

Insider Activity at Cencora

In other Cencora news, CEO Robert P. Mauch sold 4,970 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $255.00, for a total value of $1,267,350.00. Following the completion of the sale, the chief executive officer now directly owns 51,070 shares of the company's stock, valued at $13,022,850. The trade was a 8.87 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CAO Lazarus Krikorian sold 2,000 shares of the business's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $260.06, for a total transaction of $520,120.00. Following the completion of the sale, the chief accounting officer now directly owns 20,154 shares of the company's stock, valued at $5,241,249.24. This represents a 9.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 11,970 shares of company stock valued at $2,998,670. Corporate insiders own 10.80% of the company's stock.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.